Bank of New York Mellon Corp Has $89.57 Million Holdings in Medpace Holdings, Inc. $MEDP

Bank of New York Mellon Corp lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.5% in the 4th quarter, HoldingsChannel reports. The fund owned 159,477 shares of the company’s stock after selling 5,752 shares during the quarter. Bank of New York Mellon Corp’s holdings in Medpace were worth $89,570,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Optiver Holding B.V. acquired a new stake in Medpace in the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace in the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new stake in Medpace in the 4th quarter valued at about $30,000. Finally, Quarry LP acquired a new stake in Medpace in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 20.50% of the company’s stock.

Medpace Trading Up 0.8%

NASDAQ:MEDP opened at $457.90 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $294.07 and a 1-year high of $628.92. The firm has a fifty day simple moving average of $456.55 and a 200 day simple moving average of $507.45. The stock has a market capitalization of $13.08 billion, a PE ratio of 28.78, a P/E/G ratio of 2.30 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the business posted $3.67 earnings per share. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MEDP. BMO Capital Markets lowered their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Barclays cut their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Mizuho set a $582.00 target price on shares of Medpace in a report on Wednesday, February 11th. Finally, Truist Financial dropped their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $467.08.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms announced or reiterated class-action filings against Medpace, urging investors who bought shares between April 22, 2025 and February 9, 2026 to contact counsel before the June 8 deadline. These repeated notices can keep legal risk in the spotlight and pressure sentiment toward Article Title.
• Negative Sentiment: Rosen Law Firm, Faruqi & Faruqi, Robbins Geller, and Safirstein Law all highlighted the same securities class action, suggesting the issue is gaining attention and could increase concerns about potential settlement costs, legal fees, or management distraction. Article Title
• Neutral Sentiment: The company’s most recent earnings report was solid, with EPS and revenue both beating estimates and revenue up sharply year over year. That helps explain why some investors may view the legal-driven weakness as separate from operating performance.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.